Evidence map›Paper›PMID 32607598›Full record

Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2021

Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy-a randomised controlled trial.

Terry Trinh, Susanna B Park, Jenna Murray, Hannah Pickering, Cindy S-Y Lin, Andrew Martin, Michael Friedlander, Matthew C Kiernan, David Goldstein, Arun V Krishnan

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Chemotherapy and peripheral neuropathy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Terry TrinhPrince of Wales Clinical School, University of New South Wales, Sydney, Australia.
Susanna B ParkBrain and Mind Centre, University of Sydney, Sydney, Australia.
Jenna MurrayPrince of Wales Clinical School, University of New South Wales, Sydney, Australia.
Hannah PickeringPrince of Wales Clinical School, University of New South Wales, Sydney, Australia.
Cindy S-Y LinBrain and Mind Centre, University of Sydney, Sydney, Australia.
Andrew MartinNational Health and Medical Research Centre Clinical Trials Centre, University of Sydney, Sydney, Australia.
Michael FriedlanderDepartment of Medical Oncology, Prince of Wales Hospital, Randwick, Sydney, Australia.
Matthew C KiernanBrain and Mind Centre, University of Sydney, Sydney, Australia.
David GoldsteinPrince of Wales Clinical School, University of New South Wales, Sydney, Australia.
Arun V KrishnanPrince of Wales Clinical School, University of New South Wales, Sydney, Australia. arun.krishnan@unsw.edu.au.
UNSW Sydney · AUUniversity of Sydney · AUNational Health and Medical Research Council · AUPrince of Wales Hospital · AU

Funding

Cancer Institute NSW 14/TPG/1-05National Health and Medical Research Council 1007628
6 · The paper itself

Abstract

TRIAL

designPeripheral neuropathy is a commonly reported adverse effect of oxaliplatin treatment, representing a significant limitation which may require discontinuation of effective therapy. The present study investigated the neuroprotective potential of riluzole in patients undergoing oxaliplatin treatment in a randomised-controlled trial comparing riluzole and placebo-control.

methodsFifty-two patients (17 females, 58.1 ± 12.7 years) receiving oxaliplatin treatment were randomised into either a treatment (50 mg riluzole) or lactose placebo group. The primary outcome measure was the total neuropathy score-reduced (TNSr). Secondary outcome measures include nerve excitability measures, 9-hole pegboard and FACT-GOG NTX questionnaire. Patients were assessed at baseline, pre-cycle 10 or 12, 4-week and 12-week post-treatment.

resultsBoth the treatment and placebo groups developed objective and patient reported evidence of neurotoxicity over the course of oxaliplatin treatment, although there were no significant differences across any parameters between the two groups. However, across follow-up assessments, the treatment group experienced greater neuropathy, represented by a higher TNSr score at 4-week post-chemotherapy of 8.3 ± 2.7 compared with 4.6 ± 3.6 (p = 0.032) which was sustained at 12-week post-treatment (p = 0.089). Similarly, patients in the treatment group reported worse symptoms with a FACT-GOG NTX score of 37.4 ± 10.2 compared with 43.3 ± 7.4 (p = 0.02) in the placebo group at 4-week post-treatment.

conclusionThis study is the first to provide an objective clinical investigation of riluzole in oxaliplatin-induced peripheral neuropathy employing both functional and neurophysiological measures. Although the recruitment target was not reached, the results do not show any benefit of riluzole in minimising neuropathy and may suggest that riluzole worsens neuropathy associated with oxaliplatin treatment.

Indexed as

AdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedNeuroprotectionOxaliplatinPeripheral Nervous System DiseasesRiluzoleYoung AdultOxaliplatinRiluzoleNerve excitabilityNeuropathyNeuroprotectionNeurotoxicityOxaliplatinRiluzole

Identifiers

PMID32607598
OpenAlexW3039296430

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.